Michael G. Schlossmacher

Author

Also Known As

Brit Mollenhauer, Christine Stadelmann, Earl G. Brown, John D. Rioux, John M. Woulfe, LaVoie, Matthew J., M G Schlossmacher, M Schlossmacher, M. G. Schlossmacher, M. Schlossmacher

163

Publications

15.8K

Citations

H-Index

Concepts

All Affiliations

University of Ottawa Brigham and Women's Hospital Harvard University Ottawa Hospital Ottawa Hospital Research Institute

About

Michael G. Schlossmacher is an author at University of Ottawa specializing in medicine, neuroscience, and neurology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	25	7.8K
2	Biochemistry	7	7	3.8K
3	Social Sciences	5	5	1.4K
4	Natural Sciences	4	4	3.1K
5	Health Sciences	2	2	114

Michael G. Schlossmacher

Publications

13.6K

Citations

H-Index

Page 1

	Year	Citations
Amyloid β-peptide is produced by cultured cells during normal metabolism Christian Haass, Michael G. Schlossmacher, Albert Y. Hung, Nature Amyloid β-PeptideProtein ExpressionBiochemistryNatural SciencesProtein Biosynthesis	1992	1.9K
Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein in Familial and Sporadic Lewy Body Disease John P. Anderson, Donald E. Walker, Jason Goldstein, Journal of Biological Chemistry	2006	1.4K
Ubiquitination of a New Form of α-Synuclein by Parkin from Human Brain: Implications for Parkinson's Disease Hideki Shimura, Michael G. Schlossmacher, Nobutaka Hattori, Science	2001	1K
Dopamine covalently modifies and functionally inactivates parkin Matthew J. LaVoie, Beth L. Ostaszewski, Andreas Weihofen, Nature Medicine Functional SelectivityMedicineNeurotransmitterNeuropharmacologyNeuroscience	2005	712
Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease Omar M. A. El‐Agnaf, Sultan A. Salem, Katerina E. Paleologou, The FASEB Journal PathologySoluble AggregatesNeurochemical BiomarkersOligomeric FormsDegenerative Pathology	2006	700
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study Brit Mollenhauer, Joseph J. Locascio, Walter Schulz‐Schaeffer, The Lancet Neurology Neurodegenerative DiseasesCerebrospinal FluidParkinson DiseaseNeurochemical BiomarkersCohort Study	2011	624
Molecular markers of early Parkinson's disease based on gene expression in blood Clemens R. Scherzer, Aron C. Eklund, Lee Jae Morse, Proceedings of the National Academy of Sciences	2007	513
beta-Amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms. Christian Haass, Albert Y. Hung, Michael G. Schlossmacher, Journal of Biological Chemistry Protein SecretionMolecular BiologyCytoskeletonCellular PhysiologyDistinct Cellular Mechanisms	1993	462
Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease Takahiko Tokuda, Sultan A. Salem, David Allsop, Biochemical and Biophysical Research Communications Neurodegenerative DiseasesAged IndividualsNeurobiology Of DiseaseDegenerative DiseasesCerebrospinal Fluid	2006	430
Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration Brit Mollenhauer, Valerie Cullen, Ilana Kahn, Experimental Neurology Neurodegenerative DiseasesNeurobiology Of DiseaseMedicineBiomarkersDegenerative Pathology	2008	384

Page 1